Docetaxel and Gemcitabine With Filgrastim-SD/01 Support in Patients With Advanced Non-Small Cell Lung Carcinoma

December 26, 2012 updated by: Schwartzberg, Lee, M.D.
Determine whether patients have a decreased incidence of grade 3 and grade 4 neutropenia when Filgrastim-SD/01 is given with docetaxel and gemcitabine in patients with advanced non-small cell lung cancer.

Study Overview

Status

Completed

Conditions

Intervention / Treatment

Detailed Description

Docetaxel and Gemcitabine given on day 1 and 8 of a 21-day schedule has substantial activity in non-small cell lung cancer. Both first and second-line patients have response rates comparable to or better than other standard combination regimens. Grade 3/4 neutropenia occurs in up to half of patients not given growth factor support.

Studies demonstrate that a single dose of Filgrastim-SF/01 at 100 mg/kg effectively enhances post chemotherapy neutrophil recovery in a manner similar to that of daily Filgrastim. This current study is designed to characterize the incidence of grade 3/4 neutropenia when a fixed dose of Filgrastim-SD/01 is added to a well-studied myelosuppressive chemotherapy regimen consisting of Gemcitabine and Docetaxel.

Study Type

Interventional

Enrollment (Actual)

40

Phase

  • Phase 2

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

  • United States
    • Mississippi
      • Southaven, Mississippi, United States, 38671
        • The West Clinic, PC
    • Tennessee
      • Memphis, Tennessee, United States, 38120
        • The West Clinic, PC

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years and older (Adult, Older Adult)

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Description

  • Histologically or cytologically documented non-small cell lung cancer
  • Subjects must have stage IV or IIIB NSCLC
  • 0-1 prior treatment regimens of chemotherapy
  • Subjects must have bi-dimensionally measurable disease or evaluable disease by physical exam or radiological studies
  • Age > 18 years
  • 1st Line - ECOG 0-2
  • 2nd Line - ECOG 0-1
  • Absolute neutrophil count > or = 1.5 x 10 to the 9th power/L
  • Platelet count > or = 100 x 10 to the 9th power/L
  • Adequate renal function with screening serum creatinine < or = 2.0 mg/dL
  • Adequate AST and ALT no more than 1.5 x the upper limit of normal and serum bilirubin < or = upper limit of normal
  • Subjects must be at least two weeks from prior major thoracic or abdominal surgery and at least two weeks from completion of radiation therapy, and recovered from all toxicities associated with these treatments
  • Negative HCG by urine or blood test in subject of child-bearing potential
  • Life expectancy > 2 months
  • Ethical - Before any study specific procedure is done or before study medication is administered, the subject or legally acceptable representative must give informed consent for participation in the study

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Treatment
  • Allocation: N/A
  • Interventional Model: Single Group Assignment
  • Masking: None (Open Label)

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Experimental: Filgrastim-SD/01
6 mg SC, Day 9, 24 hours after the end of the chemotherapy infusion
Drug: Filgrastim-SD/01
6 mg SC on Day 9 (24 hours after the end of the chemotherapy infusion)

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Schwartzberg, Lee, M.D.

Collaborators

Amgen

Investigators

  • Principal Investigator: Lee S Schwartzberg, MD, FACP, The West Clinic, PC

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

Helpful Links

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start

November 1, 2001

Primary Completion (Actual)

February 1, 2007

Study Completion (Actual)

February 1, 2007

Study Registration Dates

First Submitted

December 17, 2002

First Submitted That Met QC Criteria

December 17, 2002

First Posted (Estimate)

December 18, 2002

Study Record Updates

Last Update Posted (Estimate)

December 27, 2012

Last Update Submitted That Met QC Criteria

December 26, 2012

Last Verified

December 1, 2012

More Information

Terms related to this study

Keywords

Additional Relevant MeSH Terms

Other Study ID Numbers

  • SD01-20010120

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Subscribe